How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/acute-myelomonocytic-leukemia-fab-m4.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Acute myelomonocytic leukemia, FAB M4 — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Acute myelomonocytic leukemia, FAB M4 (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Acute myelomonocytic leukemia, FAB M4, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	Line of therapy	First approval
Trisenox	ARSENIC TRIOXIDE	Cephalon	High Risk QT Prolonging Agents	Potassium voltage-gated channel subfamily H member 2		2000-01-01
Trisenox	Trisenox	German AML Cooperative Group		Potassium voltage-gated channel subfamily H member 2, Thioredoxin reductase 1, cytoplasmic

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Cephalon · 1 drug in Acute myelomonocytic leukemia, FAB M4
German AML Cooperative Group · 1 drug in Acute myelomonocytic leukemia, FAB M4

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Acute myelomonocytic leukemia, FAB M4:

Cite this brief

Drug Landscape (2026). Acute myelomonocytic leukemia, FAB M4 — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/acute-myelomonocytic-leukemia-fab-m4. Accessed 2026-06-10.

Acute myelomonocytic leukemia, FAB M4 full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing